Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Adv. 2025 May 27; 9(10):2453-2457.
PMID: 39969200
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152.
PMID: 39928953
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood Cancer J. 2025 Apr 03; 15(1):55.
PMID: 40180903
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J. 2025 Mar 31; 15(1):50.
PMID: 40164584
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia.
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia. J Natl Compr Canc Netw. 2025 Mar 28; 23(3.5).
PMID: 40154394
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar 27; 145(13):1369-1381.
PMID: 40146152
Imetelstat: drugging telomerase in transfusion-dependent low- and intermediate-1-risk MDS.
Imetelstat: drugging telomerase in transfusion-dependent low- and intermediate-1-risk MDS. Blood Adv. 2025 Mar 25; 9(6):1390-1391.
PMID: 39776158
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes.
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
PMID: 39652823
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncol. 2025 Apr; 21(8):929-941.
PMID: 40051275
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. J Natl Compr Canc Netw. 2025 Mar; 23(3):66-75.
PMID: 40073835